A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Abroad (travel likely)RecruitingPHASE3

Conditions

Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Rui-Hua Xu, Guangzhou, Guangdong, China
Contact: Study coordinator (Ran Xu) · xuran@sysucc.org.cn · 020-87343565

Study leads

Rui-Hua Xu
Principal Investigator
Sun Yat-Sen University Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Colorectal Cancer (Diagnosis) · Colorectal Cancer Metastatic · Colorectal Cancer (CRC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Liverpool, Australia · Macquarie Park, Australia

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Metastatic Colorectal Adenocarcinoma · Stage IV Colorectal Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE3

Kingman, United States · Phoenix, United States

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Colorectal Cancer · Liver Metastases

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China